New Options Challenge Standard Treatments in EGFR-Mutant NSCLC
(MedPage Today) -- MADRID -- Two positive phase III trials involving amivantamab (Rybrevant)-based regimens introduced new first- and second-line options in EGFR-mutant non-small cell lung cancer (NSCLC), though toxicity with the combination...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology